NCT04080531View on ClinicalTrials.gov

Influenza Vaccination for Flu Prevention in Patients With Plasma Cell Disorders

PHASE4CompletedINTERVENTIONAL
Enrollment

165

Participants

Timeline

Start Date

October 18, 2019

Primary Completion Date

May 11, 2021

Study Completion Date

December 15, 2022

Conditions
Plasma Cell Neoplasm
Interventions
BIOLOGICAL

Pneumococcal 13-valent Conjugate Vaccine

Given IM

BIOLOGICAL

Trivalent Influenza Vaccine

Given IM

Trial Locations (2)

30308

Emory University Hospital Midtown, Atlanta

30322

Emory University Hospital/Winship Cancer Institute, Atlanta

Sponsors

Collaborators (1)

Sanofi
All Listed Sponsors
collaborator

Sanofi

INDUSTRY

collaborator

National Institutes of Health (NIH)

NIH

collaborator

National Cancer Institute (NCI)

NIH

lead

Emory University

OTHER